Immune Metabolism Dysregulation and Efficacy to Anti-PD-1 PD-L1 Agents in Non Small Cell Lung Cancer Patients

Summary

Prospective, biological, observational study involving the collection and use of samples from patients suffering from NSCLC lung cancer, aimed at comparing the molecular profile related to metabolism among subjects with response or resistance to checkpoint inhibitors immune system (ICI), in order to contribute to define response biomarkers and new molecular pathways as therapeutic targets combine with ICI to overcome resistance.

Eligibility

Inclusion Criteria:

* Age \> 18 years
* Histological diagnosis of advanced stage NSCLC
* Histotype adenocarcinoma and squamous carcinoma
* ECOG PS \<2
* Known PDL-1 stage
* Measurable disease
* Availability of tumor tissue
* No evidence of molecular drivers
* Written informed consent (to the study and data processing)

For the second cohort in addition to the precedents it is included

* Diagnosis of limited or locally advanced NSCLC deemed resectable

For the third cohort in addition to the precedents it is included

* patients candidates for surgery for non-small cell lung cancer

Exclusion Criteria:

* Contraindications to immunotherapy
* Unavailability of tumor tissue
* Histotype with neuroendocrine or mixed component

For the second cohort

* Contraindication to immunotherapy
* Histotype with neuroendocrine or mixed component
* Locally advanced disease candidate for concomitant chemo-radiotherapy treatment

For the third cohort

* previously treated patients

Conditions3

Browse More Trials